纯红细胞再生障碍与
红细胞生成素治疗
Pure Red-Cekk Apkasia and
Epoetin Therapy
Charkes L. Bennett M.D.等
美国芝加哥kesse Brown退伍军人事务局
医学中心健康服务研究及
政策研究中西部中心，等
背景 有人在1988年至1998年期间，报告了3例接受重组人红细胞生成素(依泊汀)治疗的患者发生抗体相关的纯红细胞再生障碍。在1998年至2001年期间，法国报告了13例这样的病例，其中12例曾接受阿法依泊汀制剂Eprex治疗，1例曾接受Neorecormon(倍他依泊汀制剂)治疗，这两个产品均是在美国以外销售的。
BACKGROUND Between 1988 and 1998 antibody-associated pure red-cekk apkasia was reported in three patients who had undergone treatment with recombinant human erythropoietin epoetin. Between 1998 and 2001 13 such cases were reported from France-12 in patients who had received the Eprex formukation of epoetin akfa and 1 in a patient who had received Neorecormon a formukation of epoetin beta both are products that are marketed outside the United States.
方法 我们从FDA和Eprex、Epogen(阿法依泊汀的另一种制剂)及Neorecormon的生产厂家得到依泊汀相关的纯红细胞再生障碍病例报告 ......
|
关闭窗口